icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Substantial
Substantial in the treatment of SJIA.
Clinical Added Value
moderate
Like ROACTEMRA (tocilizumab), ILARIS (canakinumab) provides a moderate improvement in actual benefit (level III) in the management of patients aged 2 years and older, with active systemic juvenile idiopathic arthritis, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.
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
rN8rG9wqbsXVgVmL